PCRX.US Pacira BioSciences, Inc.

Healthcare Pharmaceuticals USA Stocks
36.48 USD
Close of Nov 16, 2026
18.80 36.67
Market cap
USD 1.46B
P/E
39.2x
P/B
2.04x
ROE
6.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is PCRX.US undervalued?

Graham number
Price36.48
Graham value19.33
Premium88.7%

PCRX.US trades 88.7% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Pacira BioSciences, Inc. fundamental analysis

No fundamental analysis for Pacira BioSciences, Inc. yet.

Pacira BioSciences, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Pacira BioSciences, Inc.

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a …

Full company profile